EP Patent

EP3698793A1 — Besifloxacin for the treatment of resistant acne

Assigned to Vyome Therapeutics Ltd · Expires 2020-08-26 · 6y expired

What this patent protects

The present disclosure relates to formulations comprising besifloxacin for use in the treatment of acne and more specifically resistant acne.

USPTO Abstract

The present disclosure relates to formulations comprising besifloxacin for use in the treatment of acne and more specifically resistant acne.

Drugs covered by this patent

isavuconazonium-sulfate (ISAVUCONAZONIUM SULFATE)

Patent Metadata

Patent number: EP3698793A1
Jurisdiction: EP
Classification: —
Expires: 2020-08-26
Drug substance claim: No
Drug product claim: No
Assignee: Vyome Therapeutics Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.